Piclib (Palbociclib) 125 mg is a highly effective targeted antineoplastic medication containing palbociclib as its active ingredient. It belongs to the class of selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Piclib is indicated for targeted therapy of locally advanced or metastatic breast cancer. Administered in combination with an aromatase inhibitor or fulvestrant, it blocks malignant cell proliferation and delays disease progression.
Manufacturer: Hetero Healthcare Ltd. / Hetero Labs Limited, India. Hetero is a renowned global pharmaceutical company specializing in high-quality generic and oncology products manufactured under strict compliance with GMP, US FDA, and WHO standards to ensure patient safety and product efficacy.
Key Advantages and Features of Piclib 125 mg:
- ✅ Targeted Mechanism of Action: Specifically blocks CDK4/6 enzymes responsible for cancer cell cycle progression.
- ✅ Proven Efficacy: Extends progression-free survival in patients with HR-positive, HER2-negative advanced breast cancer.
- ✅ Convenient Dosing Schedule: Oral capsule regimen with a standard 21 days ON, 7 days OFF treatment cycle.
- ✅ Global Quality Standard: Manufactured by Hetero under stringent international pharmaceutical quality standards.